Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypoglycemic agents and circulating cytokines in metabolic-related diseases
ChiCTR1800019776Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin in cardiometabolic risk (CMR) and metabolic syndrome (MS) (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Circulating cytokines. Started Nov 2018; status: recruiting.
02
Drugs
metformin
03
Conditions
cardiometabolic risk (CMR)metabolic syndrome (MS)
Beyond the preview
Go deeper on ChiCTR1800019776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019776.